Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023
About a century ago, the link between NAD + and health were first established by Conrad Elvehjem, who discovered that pellagra (characterized by dementia, dermatitis, and diarrhea) was caused by a dietary deficiency of niacin (NAD + precursor) in 1937 [21]
This therapy does not cause any harmful effects
Phase 2 liver disease data published in Nature Medicine (2024) identifies retatrutide as the compound with the most comprehensive hepatic fat reduction profile currently under clinical investigation, making it the correct peptide for NAFLD and MASH preclinical study designs
Its a more holistic and, in our professional opinion, a more sustainable approach to long-term health and performance research